Format

Send to:

Choose Destination
See comment in PubMed Commons below
Am J Bioeth. 2008 Jun;8(6):5-8. doi: 10.1080/15265160802248179.

Direct to confusion: lessons learned from marketing BRCA testing.

Author information

  • 1Yale Cancer Center, 55 Church Street, Suite 402, New Haven, CT 06520, USA. ellen.matloff@yale.edu

Abstract

Myriad Genetics holds a patent on testing for the hereditary breast and ovarian cancer genes, BRCA1 and BRCA2, and therefore has a forced monopoly on this critical genetic test. Myriad launched a Direct-to-Consumer (DTC) marketing campaign in the Northeast United States in September 2007 and plans to expand that campaign to Florida and Texas in 2008. The ethics of Myriad's patent, forced monopoly and DTC campaign will be reviewed, as well as the impact of this situation on patient access and care, physician liability, and the future of DTC campaigns for genetic testing.

PMID:
18726769
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Write to the Help Desk